CoChat

Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial

Open access
Zhang, Yuqin, Qu, Zhihua, Lu, Ting, Shao, Xiaowen, Cai, Meili, Dilimulati, Diliqingna, Gao, Xinxin, Mao, Weiqing, Hu, Fan, Su, Lili, Liao, Qiong, Han, Ting, Zhang, Manna, Qu, Shen · 2023 · Nutrients
Cited by 45

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

The effects of dulaglutide and a calorie-restricted diet (CRD) on visceral adipose tissue (VAT) and metabolic profiles in polycystic ovary syndrome (PCOS) have not been extensively investigated. In this study, we investigated whether dulaglutide combined with CRD could further reduce VAT and promote clinical benefits as compared with a CRD regimen alone in overweight or obese PCOS-affected women. Between May 2021 and May 2022, this single-center, randomized, controlled, open-label clinical trial was conducted. Overall, 243 participants with PCOS were screened, of which 68 overweight or obese individuals were randomly randomized to undergo dulaglutide combined with CRD treatment (n = 35) or CRD treatment alone (n = 33). The duration of intervention was set as the time taken to achieve a 7% weight loss goal from baseline body weight, which was restricted to 6 months. The primary endpoint was the difference in the change in VAT area reduction between the groups. The secondary endpoints contained changes in menstrual frequency, metabolic profiles, hormonal parameters, liver fat, and body composition. As compared with the CRD group, the dulaglutide + CRD group had a considerably shorter median time to achieve 7% weight loss. There was no significant between-group difference in area change of VAT reduction (−0.97 cm2, 95% confidence interval from −14.36 to 12.42, p = 0.884). As compared with CRD alone, dulaglutide + CRD had significant advantages in reducing glycated hemoglobin A1c and postprandial plasma glucose levels. The results of the analyses showed different changes in menstruation frequency, additional metabolic profiles, hormonal markers, liver fat, and body composition between the two groups did not differ significantly. Nausea, vomiting, constipation, and loss of appetite were the main adverse events of dulaglutide. These results emphasize the value of dietary intervention as the first line of treatment for PCOS-affected women, while glucagon-like peptide 1 receptor agonist therapy provides an efficient and typically well tolerated adjuvant therapy to aid in reaching weight targets based on dietary therapy in the population of overweight/obese PCOS-affected women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu15030556

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. Petraglia, 2003, Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome, Endocr. Rev., 24, 633, 10.1210/er.2002-0015 · DOI · Paper page
  2. Hoeger, 2006, Role of lifestyle modification in the management of polycystic ovary syndrome, Best Pract. Res. Clin. Endocrinol. Metab., 20, 293, 10.1016/j.beem.2006.03.008 · DOI
  3. Lim, S., Smith, C.A., Costello, M.F., MacMillan, F., Moran, L., and Ee, C. (2019). Barriers and facilitators to weight management in overweight and obese women living in Australia with PCOS: A qualitative study. BMC Endocr. Disord., 19. · DOI · Paper page
  4. Yoshimura, 2014, Lifestyle Intervention Involving Calorie Restriction with or without Aerobic Exercise Training Improves Liver Fat in Adults with Visceral Adiposity, J. Obes., 2014, 197216, 10.1155/2014/197216 · DOI · Paper page
  5. Huffman, K.M., Redman, L.M., Landerman, L.R., Pieper, C.F., Stevens, R.D., Muehlbauer, M.J., Wenner, B.R., Bain, J.R., Kraus, V.B., and Newgard, C.B. (2012). Caloric Restriction Alters the Metabolic Response to a Mixed-Meal: Results from a Randomized, Controlled Trial. PLoS ONE, 7. · DOI · Paper page
  6. Dawson, 2019, The Effect of Exenatide on Cardiovascular Risk Markers in Women with Polycystic Ovary Syndrome, Front. Endocrinol., 10, 189, 10.3389/fendo.2019.00189 · DOI · Paper page
  7. Liu, 2017, Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome, Clin. Endocrinol., 87, 767, 10.1111/cen.13454 · DOI · Paper page
  8. Amblee, 2016, Mode of administration of dulaglutide: Implications for treatment adherence, Patient Prefer. Adherence, 10, 975, 10.2147/PPA.S82866 · DOI · Paper page
  9. Eleni, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), Hum. Reprod., 19, 41, 10.1093/humrep/deh098 · DOI · Paper page
  10. Huang, 2005, One-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study, Am. J. Gastroenterol., 100, 1072, 10.1111/j.1572-0241.2005.41334.x · DOI · Paper page
  11. Eckel, 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129, S76, 10.1161/01.cir.0000437740.48606.d1 · DOI · Paper page
  12. Dhaliwal, 2019, Changes in Visceral and Subcutaneous Fat in Youth with Type 2 Diabetes in the Today Study, Diabetes Care, 42, 1549, 10.2337/dc18-1935 · DOI
  13. Bredella, 2013, Assessment of Abdominal Fat Compartments Using DXA in Premenopausal Women from Anorexia Nervosa to Morbid Obesity: DXA for Assessment of Abdominal Fat, Obesity, 21, 2458, 10.1002/oby.20424 · DOI
  14. Panizza, C.E., Lim, U., Yonemori, K.M., Cassel, K.D., Wilkens, L.R., Harvie, M.N., Maskarinec, G., Delp, E.J., Lampe, J.W., and Shepherd, J.A. (2019). Effects of Intermittent Energy Restriction Combined with a Mediterranean Diet on Reducing Visceral Adiposity: A Randomized Active Comparator Pilot Study. Nutrients, 11. · DOI · Paper page
  15. Nylander, 2017, Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: A randomized clinical trial, Reprod. Biomed. Online, 35, 121, 10.1016/j.rbmo.2017.03.023 · DOI · Paper page
  16. Suliburska, 2016, The effects of a low-calorie diet or an isocaloric diet combined with metformin on sex hormones in obese women of child-bearing age, Acta Sci. Pol. Technol. Aliment., 15, 213, 10.17306/J.AFS.2016.2.21 · DOI
  17. Sookthai, 2018, Effects of intermittent and continuous calorie restriction on body weight and metabolism over 50 wk: A randomized controlled trial, Am. J. Clin. Nutr., 108, 933, 10.1093/ajcn/nqy196 · DOI · Paper page
  18. Tapsell, 2010, Short term effects of energy restriction and dietary fat sub-type on weight loss and disease risk factors, Nutr. Metab. Cardiovasc. Dis., 20, 317, 10.1016/j.numecd.2009.04.007 · DOI · Paper page
  19. Ferdinand, 2014, Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients with Type 2 Diabetes Mellitus, Hypertension, 64, 731, 10.1161/HYPERTENSIONAHA.114.03062 · DOI · Paper page
  20. Bagheri, 2018, Lipid profile change after bariatric surgeries: Laparoscopic gastric plication versus mini gastric bypass, Acta Chir. Belg., 119, 146, 10.1080/00015458.2018.1479022 · DOI
  21. Seko, 2017, Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus, Hepatol. Res., 47, 1206, 10.1111/hepr.12837 · DOI · Paper page
  22. Cunha, 2020, Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients with Obesity, Front. Endocrinol., 11, 607, 10.3389/fendo.2020.00607 · DOI · Paper page
  23. Ahangari, 2018, The effect of vitamin D supplementation in combination with low-calorie diet on anthropometric indices and androgen hormones in women with polycystic ovary syndrome: A double-blind, randomized, placebo-controlled trial, J. Endocrinol. Investig., 41, 597, 10.1007/s40618-017-0785-9 · DOI
  24. Guo, 2020, Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials, Diabetes Ther., 11, 1821, 10.1007/s13300-020-00869-z · DOI
  25. Svendsen, 2018, Effect of intermittent versus continuous energy restriction on weight loss, maintenance and cardiometabolic risk: A randomized 1-year trial, Nutr. Metab. Cardiovasc. Dis., 28, 698, 10.1016/j.numecd.2018.03.009 · DOI · Paper page
  26. Keenan, S., Cooke, M.B., Chen, W.S., Wu, S., and Belski, R. (2022). The Effects of Intermittent Fasting and Continuous Energy Restriction with Exercise on Cardiometabolic Biomarkers, Dietary Compliance, and Perceived Hunger and Mood: Secondary Outcomes of a Randomised, Controlled Trial. Nutrients, 14. · DOI
  27. Nylander, 2018, Quantification of visceral adipose tissue in polycystic ovary syndrome: Dual-energy X-ray absorptiometry versus magnetic resonance imaging, Acta Radiol., 59, 13, 10.1177/0284185117711475 · DOI

Cited by

See all 45

Metadata

Authors
Zhang, Y., Qu, Z., Lu, T., Shao, X., Cai, M., Dilimulati, D., Gao, X., Mao, W., Hu, F., Su, L., Liao, Q., Han, T., Zhang, M., & Qu, S.
Venue
Nutrients
Publisher
MDPI AG
Published
2023-01-20
Volume
15
Issue
3
Pages
556
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4317733039
Cited by
45
References
25
FWCI
8.66
Type
journal article
Language
en
Open access
gold
Funders
National Nature Science Foundation (81601269)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.